Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01185132 · ClinicalTrials.gov registry record · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
A Phase 3 study of Breast Cancer, sponsored by Rocky Mountain Cancer Centers.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
- 5
- Study locations
NCT01185132 is a Phase 3 study of Breast Cancer that is actively recruiting participants, run by Rocky Mountain Cancer Centers. The registered enrollment target is 660 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT01185132, a Phase 3 study of Breast Cancer, is actively recruiting participants, sponsored by Rocky Mountain Cancer Centers.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
- 5
- Study locations
Study Summary
In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, spares more normal breast and lung tissue, and may lead to improved clinical outcomes.
Conditions Studied
Interventions
- RADIATION accelerated partial breast irradiation - 3D-conformal planning
- RADIATION accelerated partial breast irradiation - IMRT planning
Study Locations (5)
Colorado
- Rocky Mountain Cancer Centers - Aurora - Aurora
- Rocky Mountain Cancer Centers - Boulder - Boulder
- Rocky Mountain Cancer Centers - Lakewood - Lakewood
- Rocky Mountain Cancer Centers - Littleton - Littleton
- Rocky Mountain Cancer Centers - Thornton - Thornton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2009-07 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01185132
The ClinicalTrials.gov registry entry for NCT01185132 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Rocky Mountain Cancer Centers, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which accelerated partial breast irradiation - 3D-conformal planning is the first listed.
NCT01185132 reports 5 study locations spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01185132 about?
NCT01185132 is a clinical study titled "Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy". In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, sp...
What is the current status of trial NCT01185132?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2009-07. Estimated completion is 2028-07.
What conditions does trial NCT01185132 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01185132?
The interventions under investigation include: accelerated partial breast irradiation - 3D-conformal planning (RADIATION), accelerated partial breast irradiation - IMRT planning (RADIATION).
Who is sponsoring clinical trial NCT01185132?
This trial is sponsored by Rocky Mountain Cancer Centers, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01185132 being conducted?
This trial has 5 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.